Evotec SE has appointed Dr. Sarah Fakih as Executive Vice President, Head of Global Communications and Investor Relations. In this strategic role, Fakih will lead Evotec’s newly integrated Global Communications and Investor Relations function.

Reporting directly to CEO Dr. Christian Wojczewski, Fakih will bring together both teams to strengthen alignment, clarity and engagement across stakeholders. The integration of Communications and Investor Relations supports Evotec’s focus on a clear and consistent articulation of its strategy, scientific leadership and value creation. The appointment follows the departure of Volker Braun, who successfully led Evotec’s Investor Relations and ESG function over the past five years.

Fakih brings more than 15 years of experience in life sciences, with a strong leadership track record in capital markets strategy and corporate messaging. She has held senior roles at U.S. listed companies, including QIAGEN, MorphoSys, and most recently at CureVac. She holds a PhD in Chemistry.

Christian Wojczewski said: “Clear and credible communication is essential as we continue to execute our strategy. Sarah’s extensive experience across science, investor relations and corporate communications makes her ideally suited to this role.”